CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,163,748
- in 1 filing
Net −$1,163,748. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-27 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award | +9,338 | 91,582 | ||
| 2024-02-27 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award | +6,465 | 98,047 | ||
| 2024-02-27 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +30,640 | 224,894 | ||
| 2024-02-27 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +13,326 | 238,220 | ||
| 2024-02-27 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +9,238 | 247,458 | ||
| 2024-02-27 | BIENAIME JEAN JACQUES Director | Grant or award | +82,700 | 502,302 | ||
| 2024-02-27 | BIENAIME JEAN JACQUES Director | Grant or award | +35,975 | 538,277 | ||
| 2024-02-27 | BIENAIME JEAN JACQUES Director | Grant or award | +24,926 | 563,203 | ||
| 2024-02-27 | BIENAIME JEAN JACQUES Director | Sale | −1,000 | $90.35 | $90K | 562,203 |
| 2024-02-09 | BIENAIME JEAN JACQUES Director | Exercise or conversion 10b5-1 | +15,000 | $63.10 | $947K | 434,602 |
| 2024-02-09 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −15,000 | $88.28 | $1.3M | 419,602 |
| 2024-02-09 | BIENAIME JEAN JACQUES Director | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −15,000 | 131,000 | ||
| 2024-02-08 | BIENAIME JEAN JACQUES Director | Exercise or conversion 10b5-1 | +15,000 | $63.10 | $947K | 434,602 |
| 2024-02-08 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −15,000 | $89.77 | $1.3M | 419,602 |
| 2024-02-08 | BIENAIME JEAN JACQUES Director | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −15,000 | 146,000 | ||
| 2024-01-18 | BIENAIME JEAN JACQUES Director | Other acquisition 10b5-1 | +40 | $92.60 | $4K | 419,602 |
| 2024-01-10 | BIENAIME JEAN JACQUES Director | Exercise or conversion 10b5-1 | +10,000 | $63.10 | $631K | 435,162 |
| 2024-01-10 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −10,000 | $96.38 | $964K | 425,162 |
| 2024-01-10 | BIENAIME JEAN JACQUES Director | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 161,000 | ||
| 2024-01-09 | BIENAIME JEAN JACQUES Director | Exercise or conversion 10b5-1 | +10,000 | $63.10 | $631K | 435,162 |
Page 11 of 23 · 450 trades